NCT06627647 2026-02-12
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca
Phase 3 Recruiting
AstraZeneca
Sichuan Baili Pharmaceutical Co., Ltd.
Shanghai Shengdi Pharmaceutical Co., Ltd
Sichuan Cancer Hospital and Research Institute
Tianjin Medical University Cancer Institute and Hospital
The First Affiliated Hospital of Nanchang University